Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2018
Filed with the SEC on Feb 13, 2019 and accepted by EDGAR at Feb 13, 2019, 21:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-10-01 to 2018-12-31 | $870.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2018-01-01 to 2018-12-31 | $3.05bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2018-10-01 to 2018-12-31 | $122.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2018-01-01 to 2018-12-31 | $409.5m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2018-10-01 to 2018-12-31 | $437.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2018-01-01 to 2018-12-31 | $1.42bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-10-01 to 2018-12-31 | $153.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2018-01-01 to 2018-12-31 | $557.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-10-01 to 2018-12-31 | $127.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2018-01-01 to 2018-12-31 | $635.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2018-10-01 to 2018-12-31 | −$1.49bn | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2018-01-01 to 2018-12-31 | −$1.49bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-10-01 to 2018-12-31 | $1.55bn | us-gaap:NetIncomeLoss |
| Net income | 12 months2018-01-01 to 2018-12-31 | $2.10bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-10-01 to 2018-12-31 | $5.97 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2018-01-01 to 2018-12-31 | $8.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-10-01 to 2018-12-31 | $6.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2018-01-01 to 2018-12-31 | $8.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-10-01 to 2018-12-31 | 259,812,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2018-01-01 to 2018-12-31 | 259,185,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2018-01-01 to 2018-12-31 | $1.27bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-01-01 to 2018-12-31 | $95.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2018-01-01 to 2018-12-31 | $350.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2018-12-31 | $2.65bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-12-31 | $3.84bn | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $6.25bn | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $1.12bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-12-31 | $1.81bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-12-31 | $4.44bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-19-000006. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.